Non-Rhabdomyosarcoma Soft Tissue Sarcomas in Children: A Surveillance, Epidemiology, and End Results Analysis Validating COG Risk Stratifications
Timothy V. Waxweiler(University of Colorado Denver), Arthur K. Liu(University of Colorado Denver), Nicholas G. Cost(University of Colorado Denver), Michelle S. Proper(Billings Clinic), Timothy Garrington(Children's Hospital Colorado), Margaret E. Macy(Children's Hospital Colorado), Carrye Cost(University of Colorado Anschutz Medical Campus), Brian Greffe(University of Colorado Denver), Nathan Donaldson(University of Colorado Denver), Chad G. Rusthoven(University of Colorado Cancer Center), Travis Heare(University of Colorado Denver)
Cited by 33
Related Papers
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
|The Lancet Oncology|2019|341